NO donors in glioma therapy: can we improve the efficacy of temozolomide chemotherapy?

Astrid Weyerbrock, Stefanie Bette, Anna Werres, Nikolaos Psarras, Brunhilde Baumer, Claudia Weidensteiner & Wilfried Reichardt
Objective: Chemoresistance to temozolomide (TMZ) and insufficient drug delivery into intracranial neoplasms impair the efficacy of glioma therapy. JS-K, a diazeniumdiolate activated to release high levels of NO by glutathione-S-transferase (GST) enzymes, inhibits tumor cell growth in vitro and in vivo[for full text, please go to the a.m. URL]